Anaesthesia in an adult with Rubinstein±Taybi syndrome
EditorÐTwigg and Cook 1 have made an interesting contribution to anaesthesia for Rubinstein±Taybi syndrome in an adult. This complements reports of anaesthesia in children with this syndrome. Baer and colleagues 2 described anaesthesia in two children and reported no problems. Airway problems may be expected, as Hennekam 3 and colleagues found micrognathia or retrognathia in about half of the 45 patients they reviewed. A further paper by these workers showed 84% of these patients have microstomia, which might have an effect on laryngoscopy. 4 These two reports are in children and the descriptions of anaesthesia are sketchy. Hennekam and colleagues, in their series of 45 cases, recorded three instances of dif®culties attributable to laryngeal collapse and dif®culty in intubation. Stevens and colleagues 5 reviewed the medical problems of 50 such patients and noted frequent hospitalizations and operations (210) , showing that although Rubinstein±Taybi syndrome is rare, each patient may undergo multiple anaesthetics, an average of 2.7 each. He reported problems in nine cases. These included respiratory distress, apnoea and prolonged anaesthesia.
Hennekam's team 6 has also elucidated the genetic de®cit. This is a microdeletion on chromosome 16. Recent interest in the human genome project means that this segment of chromosome has now been sequenced. The protein from the affected gene is CREB binding protein. This protein is used in the biochemistry of every cell in that it assists cAMP and is needed to read DNA. The mutation halves the amount present in each cell. This is termed haplo-insuf®ciency. It is remarkable that disruption of this protein at a fundamental point in the cell cycle gives a syndrome as benign as Rubinstein±Taybi. Hennekam found that the incidence of the disease was around 1 in 90 000 (personal communication to ORD). Twigg 1 discusses Stirts' report 7 on cardiac arrest after the use of succinylcholine in these children. However, in another of their references, Critchley 8 and colleagues used it without ill effect. So the jury is still out on the question of the safety of succinylcholine in these patients.
We had previously found a laryngeal mask very suitable in a patient with Rubinstein±Taybi syndrome.
9 Our patient had a slow recovery after we gave an anaesthetic with propofol and spontaneous respiration. We notice that Twigg and Cook took precautions against aspiration.
1 They used an H 2 blocker as a premedicant and passed an orogastric tube; but when their patient was found to be a grade 2 view at direct laryngoscopy and so could have been intubated easily, they did not intubate. We wondered how they would have defended their anaesthetic if their patient, whom they had previsaged might vomit and aspirate, had gone on to do so. While we congratulate Twigg and Cook on the successful outcome of this case, we feel that an unnecessary risk was taken in the conduct of the anaesthetic. O. R. Dearlove R. Perkins Manchester, UK EditorÐWe are grateful for Dr Dearlove and Dr Perkins' interest in our report and for the opportunity to reply to their comments. They agree with our ®ndings that there are few reports in the literature and that these relate to paediatric problems, with no reports of anaesthetic techniques used in adults.
1 It is indeed noteworthy that the genetic defect involving the CREB binding protein is at a fundamental part of the cell cycle, and involves chromosomal rearrangements of the cytogenetic band 16p13.3, with an incidence at around 1 in 125 000 births.
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The phenotypic syndrome of Rubinstein±Taybi syndrome is markedly variable, and we would suggest that an anaesthetic assessment needs to be made on an individual basis.
1 The patient we described had no history of re¯ux, aspiration or recurrent chest infections, and we considered her to be at more risk from dif®cult intubation than regurgitation. However, communication problems meant that an entirely reliable history was not available. The use of an H 2 blocker as premedicant was sensible because the potential risk of regurgitation, however small, could not be eliminated. The passage of an orogastric tube, likewise, was safe and prudent and con®rmed that the stomach was empty. The choice of ProSeal LMA ² (PLMA) was made on the basis of it being the best airway device for this particular operation (bilateral phaecoemulsi®cation), in this particular patient. We had no objective evidence to support a history of re¯ux, but the patient had clear physical ®ndings suggesting a high risk of dif®culty with intubation. Had we considered the risk of regurgitation to be high, we would have had to choose between a rapid sequence induction in a patient with a high potential for dif®cult intubation, or an awake ®breoptic intubation in a patient with marked comprehension dif®culties. Laryngoscopy was performed in order to document the degree of dif®culty in obtaining a view of the glottis, should the patient require intubation in the future. We believe that all measures were taken to minimize potential and actual risk during this anaesthetic and that the correct technique was chosen.
Rather confusingly, Dearlove and Perkins report using a classic laryngeal mask airway (LMA) in a patient with Rubinstein±Taybi syndrome. 9 Without further details, it is dif®cult to comment and certainly we would not criticise this, but we are somewhat surprised at their criticism of our use of the PLMA in the face of their use of a classic LMA. The case they report would likely have taken place before the PLMA became available and presumably, like our patient, was judged clinically to have a low risk of regurgitation of gastric contents. In individual cases, with appropriate assessment, it may be that either the classic LMA or PLMA may be suitable for use in patients with Rubinstein±Taybi syndrome. However, the PLMA is a useful addition to the airway armamentarium, and as it is designed to separate the gastrointestinal and respiratory tracts, 11 compared with the classic LMA, it may increase the margin of safety in those patients with Rubinstein±Taybi syndrome in whom use of a tracheal tube is not considered necessary. Safe dose of levobupivacaine (Chirocaine â ) in caudal analgesia in children EditorÐCaudal analgesia is commonly used for postoperative pain relief in children of all ages having surgery below the diaphragm, as con®rmed in Sanders' recent survey of UK practice of paediatric regional anaesthesia.
1 Bupivacaine is named as the most common local anaesthetic drug of choice, and it would have been interesting to know what dose of local anaesthetic was used. The isomer levobupivacaine (Chirocaine â ) is now regularly used in the Manchester Children's Hospitals, for theoretical reasons of improved safety.
2 I have conducted an audit, looking retrospectively at the doses of levobupivacaine used in the caudal space over the last six months by anaesthetists at Booth Hall Children's Hospital in Manchester.
I studied the operating theatres' recovery book, and extracted the case numbers of all patients recorded as having caudal analgesia during the period March to September, 2002. I then looked at the patient records and noted the dose of local anaesthetic used and the weight of the patient. I calculated the dose of levobupivacaine received in mg kg ±1 and plotted this on a scatter chart (Fig. 1 ).
There were 79 caudals recorded as having been performed, but only 44 (56%) case records were present in the medical records department at Booth Hall. Twenty records were absent with unknown whereabouts, eight records were held at another hospital site, and seven were tagged as absent (e.g. for clinic appointment). Surgical operations ranged from inguinal herniotomies [32/79 (41%)], to circumcision, orchidopexy, hydrocoele repair, and exploration of testicular torsion. The weights of the children ranged from 2.8 to 59 kg, and ages ranged from 8 days to 14 yr with 64/79 (81%) being <6 yr old. An aseptic technique was recorded as being used by the anaesthetist in 34/44 (77%) of the records. A 22-gauge Jelco â cannula was used in 28/44 (64%) of cases, a 20G in six cases, 18G in two, 24G in one, 21G needle in one, and no reference was made in ®ve cases. The local anaesthetic used was plain 2.5 mg ml ±1 levobupivacaine (Chirocaine â ) in all but two cases, who received bupivacaine 0.25% with epinephrine (1 in 200 000) at a dose of 2.5 mg kg ±1 . The dose of levobupivacaine was in excess of the possible limit of 2 mg kg ±1 for bupivacaine in 16/44 (36%) of patients. The majority of these patients were <20 kg. Three patients weighing >30 kg received relatively low doses of local anaesthetic, but they also had clonidine (range 1±1.5 mg kg ±1 ) added to the caudal space. No other adjuvants were used.
Although levobupivacaine 1.25 mg kg ±1 each side is recommended for ilio-inguinal nerve block, 3 there is no evidence to support the recommended maximum dose of levobupivacaine for caudal analgesia in children. Is it assumed to be the same as the limit recommended for bupivacaine at 2 mg kg ±1 (although this drug is not yet licensed for use in children)? In this audit, more than one-third of patients received a dose in excess of this, but came to no harm. Further formal studies are needed, but I have shown that administering a dose of levobupivacaine 2.5 mg kg ±1 into the caudal space in children is a common practice at our hospital and has produced no clinical problems.
R. H. Smith Manchester, UK
EditorÐThank you for the opportunity to reply to Dr Smith's letter on the dosing of levobupivacaine in paediatric caudal analgesia. Although much potentially valuable data was not analysed from the 35/79 (44%) medical records, which could not be located, some interesting points arose.
In 42/44 (95%) of caudals in Smith's report, levobupivacaine was the local anaesthetic of choice. In my survey, levobupivacaine was used by only 7/210 (3%) of respondents.
1 It is exciting to see development and change for the patients' bene®t in our practice, brought about by new evidence on the possible reduced toxicity of levobupivacaine compared with bupivacaine. This is the sort of fact-based, highly transferable knowledge alluded to in my paper that can spread rapidly in the medical community. In Smith's report, only 3/44 (7%) of local anaesthetic doses had an adjuvant added. Lack of opiate adjuvants could be because the cases reported were suitable for day surgery. Of more interest, is the lack of use of epinephrine. Although the interpretation of test doses can be dif®cult in the anaesthetized child, many authorities recommend the use of epinephrine in test doses and monitoring for heart rate changes as well as changes in ECG morphology.
4 5 It would be useful to know how test doses were interpreted.
My survey did not attempt to record the doses of local anaesthetic used in caudal analgesia. Doses are dependent not just on weight, but also on operative site and the age of the patient. Toxicity of local anaesthetics is potentially increased in infants, and especially neonates, because of decreased plasma protein binding of the drug and increased elimination half-time. Consequently, recommended bupivacaine doses are reduced by 
